Healthcare Global Enterprises has re-appointed M/s. Rao Murthy & Associates as its Cost Auditor for the financial year 2026-27. The Board of Directors approved the re-appointment during a meeting held on August 06, 2026, ensuring continuity in statutory cost auditing services for the healthcare provider.

The appointment was made pursuant to Regulation 30(2) and (6) read with Schedule III Part A Para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also referenced SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, issued on July 11, 2023, and last updated on January 30, 2026, in its disclosure to the National Stock Exchange of India Limited and BSE Limited.

Auditor Profile

M/s. Rao Murthy & Associates is a Bengaluru-based firm established in 1994 and registered with the Institute of Cost Accountants of India under Firm Registration No. 000065. The firm is led by Mr. N. Ramaskanda (M. No. 9750) and Mr. K.R. Murali Krishna (M. No. 21622), who bring extensive experience in cost and management accounting to their roles.

With over three decades of professional service, the firm has handled various statutory assignments including cost audits, maintenance of cost records, and certifications under applicable regulations. It also provides consultancy services such as cost structure analysis, profitability studies, business planning, MIS development, and transfer pricing advisory. The firm caters to sectors including manufacturing, IT, education, and BPO.

Regulatory Compliance

The company confirmed that there are no relationships between directors and the appointed auditor that require disclosure under BSE Circular Ref no. LIST/COMP/14/2018-19 or the National Stock Exchange of India Circular Ref no. NSE/CML/2018/24 dated June 20, 2018. The detailed information regarding the re-appointment has been made available on the company's website.

The Board meeting commenced at 11.30 a.m. and concluded at 06.50 p.m. IST. Sunu Manuel, Company Secretary & Compliance Officer, signed the disclosure document on behalf of HealthCare Global Enterprises Limited.

HealthCare Global Enterprises Ltd approved a further investment of up to ₹16 crore in HCG Rajkot Hospitals LLP, its wholly owned subsidiary, during a Board meeting held on August 6, 2026. The capital injection aims to strengthen the subsidiary’s balance sheet through repayment of dues and provision of working capital, ensuring operational continuity for the cancer-specialty facility in Gujarat. This strategic allocation underscores the parent company’s commitment to sustaining its regional oncology network amidst ongoing expansion efforts.

The transaction was sanctioned under Regulation 30(2) and (6) read with Schedule III Part A Para A sub-para (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also references SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, issued on July 11, 2023, and last updated on January 30, 2026. As HCG Rajkot is a wholly owned subsidiary, the investment qualifies as a related party transaction executed on an arm’s length basis. No promoter or group company holds an interest in the entity beyond the Company’s 100% ownership.

Investment Details

The proposed outlay involves a cash consideration of up to ₹16 crore. HealthCare Global Enterprises will retain 100% control of HCG Rajkot post-investment. The company has set a deadline of September 30, 2026, for the completion of this transaction. No governmental or regulatory approvals are required for this internal capital reallocation.

Subsidiary Performance Context

HCG Rajkot operates a cancer-specialty hospital in Rajkot, Gujarat, with a licensed capacity of 147 beds, of which 134 are currently operational. Incorporated on September 22, 2017, the facility has demonstrated consistent revenue growth over the past three fiscal years.

What the Numbers Show

The subsidiary’s revenue rose to ₹60.67 crore in FY26, marking a notable acceleration from the modest growth seen between FY24 and FY25. While FY25 saw a marginal increase of approximately ₹0.12 crore over FY24, FY26 delivered a jump of roughly ₹5.18 crore. This recent uptick suggests improving utilization or pricing power at the Rajkot facility, justifying the parent company’s decision to inject fresh capital for working capital needs rather than merely covering losses.